Related Experiment Videos
Ciprofloxacin: an update on clinical experience.
The American Journal of Medicine
|April 27, 1987
Summary
Ciprofloxacin, a broad-spectrum quinolone antibiotic, demonstrated comparable efficacy to standard treatments for urinary tract, skin, and respiratory infections in clinical trials. Adverse reactions were generally mild and infrequent, with rare emergence of resistant organisms.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Trials
Background:
- Ciprofloxacin is a novel quinolone antimicrobial agent.
- It exhibits broad-spectrum activity against Gram-negative and Gram-positive organisms, including Pseudomonas aeruginosa and methicillin-resistant staphylococci.
Purpose of the Study:
- To evaluate the efficacy and safety of oral ciprofloxacin.
- To compare ciprofloxacin with standard therapeutic agents in treating various infections.
Main Methods:
- 146 clinical trials involving 3,981 patients for efficacy and 2,829 for safety.
- 44 double-blind, controlled trials compared oral ciprofloxacin with standard treatments.
- Dosages ranged from 250-750 mg twice daily, with a median of 500 mg twice daily.
Main Results:
- Ciprofloxacin (250 mg twice daily) was as effective as trimethoprim/sulfamethoxazole for urinary tract infections.
- Ciprofloxacin (750 mg twice daily) was as effective as intravenous cefotaxime for skin infections.
- Ciprofloxacin showed comparable efficacy to ampicillin for respiratory infections, with higher organism eradication rates.
Conclusions:
- Oral ciprofloxacin is an effective and safe alternative for treating common bacterial infections.
- Adverse reactions were mostly mild and transient.
- Emergence of resistant organisms was infrequent.